期刊文献+

端粒酶及蛋白亚单位在骨巨细胞瘤中的表达 被引量:2

下载PDF
导出
摘要 【目的】检测人端粒酶活性和端粒酶蛋白亚单位(human telomerase catalytic subunit,hTERT)基因在不同分级骨巨细胞瘤组织中的表达情况。【方法】收集骨巨细胞瘤样本并进行病理学分级,采用 TRAP 方法检测端粒酶活性,RT-PCR方法检测各样本中 hTERT 基因的表达,经薄层分析扫描进行定量分析。【结果】约80%的骨巨细胞瘤组织中有端粒酶活性表达,与表达组织学分级差异无统计学意义(P>0.05)。4例骨巨细胞瘤Ⅰ级样本不表达 hTERT 基因或表达极弱,13例骨巨细胞瘤Ⅱ级与3例骨巨细胞瘤Ⅲ级的样本有较高的 hTERT 基因表达水平,与骨巨细胞瘤Ⅰ级的表达差异有统计学意义(P<0.05),骨巨细胞瘤Ⅱ级与Ⅲ级的 hTERT 表达差异无统计学意义(P>0.05)。术后复发样本 hTERT 基因表达亦较其他样本明显增高。【结论】骨巨细胞瘤组织中可检测到端粒酶活性和 hTERT 基因,hTERT 基因表达量可为骨巨细胞瘤分级及生物学行为的预测提供参考。
出处 《中山大学学报(医学科学版)》 CAS CSCD 北大核心 2005年第B03期125-126,共2页 Journal of Sun Yat-Sen University:Medical Sciences
基金 中山医科大学科研启动基金(B002000011)
  • 相关文献

参考文献6

  • 1刘子君.骨关节病理学[M].北京:人民卫生出版社,1996,12..
  • 2Kamradt J, Drosse C, Kalkbrenner, et al. Telomerase activity and telomerase subunit gene expression levels are not related in prostate cancer: a real-time quantification and in situ hybridization study[J]. Lab Invest, 2003, 83(5):623-33.
  • 3Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fisson yeast and human [J]. Science, 1997, 277(5328): 955-9.
  • 4Lindvall C, Hou M, Komurasaki J, et al. Molecular characterization of human telomerase reverse transcriptase- immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene[J]. Cancer Res, 2003,63(8): 1743-7.
  • 5Weinrich SL. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTERT [J]. Nat Genet, 1997, 17(4): 498-502.
  • 6Tchirkov A, Rolhion C, Kemeny J L, et al. Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression inhuman gliomas [J], Br J Cancer, 2003, 88(4): 516-20.

共引文献13

同被引文献21

  • 1李劲松,李海刚,蔡华雄,段朝晖,沈溪明,何璇凌.明胶酶在舌鳞癌发生、演进中的表达和意义[J].中山大学学报(医学科学版),2005,26(1):109-111. 被引量:5
  • 2朱宏刚,张军,傅斌,郎斌,许凯,史涛坪,陈军,张旭.MMP-2、MMP-9及TIMP-3在膀胱移行细胞癌中的表达及临床意义[J].现代泌尿外科杂志,2007,12(1):15-17. 被引量:7
  • 3Fukata S, Inoue K, Kamada M, et al. Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ specific metastasis of renal cell carcinoma [ J ]. Cancer, 2005,103 (5) : 931-942.
  • 4Jaffe HL, Lichtenstein L, Portis RB. Giant cell tumor of bone: its pathologic appearance, grading, supposed variants and treatment[J]. Arch Pathol, 1940,30:993- 1031.
  • 5Szendroi M. Giant-cell tumor of bone[J]. J Bone Joint Surg Br, 2004,86( 1 ) : 5-12.
  • 6Komatsu K, NakanishiY,Nemoto N, et al. Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas [J]. Brain Tumor Pathol, 2004,21 (3) ; 105-112.
  • 7Declerck YA, Mercurio Proteases, extra cellular AM, Stack MS, et al. matrix, and cancer: a workshop of the path B study[J]. Am J Pathol, 2004, 164(4) : 1131-1139.
  • 8Visse R, Nagase H. Matrix metaloproteinases and tissue inhibitors of metaloproteinases : structure, function, and biochemistry [J]. CircRes, 2003,92(8) : 827-839.
  • 9Yabushita H, Shimazu M, Noguchi M, et al. Vascular endothelial growth factor activating matrix metalloproteinases in ascitic fluid during peritoneal dissemination of ovarian cancer [J]. Oncol Rep, 2003, 10( 1 ) :89-95.
  • 10Szendroi M. Giant-cell tumor of bone[J]. J Bone Joint Surg Br,2004,86(1) :5-12.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部